About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

About Market Research Forecast

U.S. Contraceptive Drugs Market

U.S. Contraceptive Drugs Market Strategic Roadmap: Analysis and Forecasts 2025-2033

U.S. Contraceptive Drugs Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channels & NGOs, Others), by Forecast 2026-2034

Jun 5 2025

Base Year: 2025

180 Pages

U.S. Contraceptive Drugs Market Strategic Roadmap: Analysis and Forecasts 2025-2033

Key Insights

The U.S. Contraceptive Drugs Market size was valued at USD 6.25 USD Billion in 2023 and is projected to reach USD 9.91 USD Billion by 2032, exhibiting a CAGR of 6.8 % during the forecast period. Oral contraceptive pills are pharmaceutical substances that are used for avoiding conception by influencing ovulation with one of them or modifying cervical mucus and sperm utilization. COCs, POPs, contraceptive patches, implants, and IUDs which don't make any sub-category, can be stated as different types of them. Such medications have a number of benefits that are given by their specific nature. Among them are high effectiveness, convenience of use, and reversible action at the moment of sudden cessation. As contraceptive methods and regular menstruation are widely used, they also address reproductive conditions which include PCOS and endometriosis. In the U.S. , market trends show a rising interest in the LARCs (long-acting reversible contraceptives) which is a good measure of their efficiency and ease of use, and women and men who want to avoid taking hormonal birth control because of side effects prefer non-hormonal methods, research shows.

U.S. Contraceptive Drugs Trends

Rising awareness of family planning and reproductive health
Increasing demand for long-acting reversible contraceptives (LARCs)
Growing preference for non-hormonal contraceptives
Technological advancements in drug delivery systems

U.S. Contraceptive Drugs Market Market Size and Forecast (2024-2030) — U.S. Contraceptive Drugs Market Company Market Share

Driving Forces: What's Propelling the U.S. Contraceptive Drugs Market

Government initiatives to promote family planning
Increasing health insurance coverage for contraception
Growing female workforce participation
Expanding awareness of contraception options for adolescents

Challenges and Restraints in the U.S. Contraceptive Drugs Market

Lack of access to affordable contraception
Religious and cultural barriers
Side effects associated with hormonal contraceptives
Limited availability of non-hormonal contraceptives

Emerging Trends in U.S. Contraceptive Drugs

Development of next-generation LARCs with lower side effects
Integration of artificial intelligence in contraception management
Telemedicine-based contraception access
Personalized contraception options based on genetic testing

Growth Catalysts in the U.S. Contraceptive Drugs Industry

Rising investment in research and development of new contraceptives
Government funding for family planning programs
Partnerships between pharmaceutical companies and non-profit organizations
Educational campaigns to promote contraception awareness

Market Segmentation: U.S. Contraceptive Drugs Analysis

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Clinics
Online Channels
Public Channels & NGOs
Others

Type:

Hormonal
- Birth control pills
- Contraceptive patches
- Contraceptive injections
- Contraceptive implants
Non-hormonal
- Condoms
- Diaphragms
- IUDs

Leading Players in the U.S. Contraceptive Drugs Market

Agile Therapeutics (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
AbbVie Inc. (U.S.)
Pfizer Inc. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Viatris Inc. (U.S.)
Amneal Pharmaceuticals, Inc. (U.S.)
Bayer AG (Germany)

Significant Developments in the U.S. Contraceptive Drugs Sector

August 2023: Lupin received U.S. FDA approval for a generic equivalent of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets, known as Turqoz.
July 2023: Opill (norgestrel) tablets received U.S. FDA approval. This marks the first nonprescription oral contraceptive for daily use.
February 2021: Amneal Pharmaceuticals, Inc. received U.S. FDA approval for its Abbreviated New Drug Application for Zafemy, the generic version of Ortho Evra, aimed at preventing pregnancy in women in February 2021.

Comprehensive Coverage U.S. Contraceptive Drugs Market Report

Our updated report delivers a comprehensive and insightful analysis of the dynamic U.S. Contraceptive Drugs Market, providing critical data and strategic perspectives for informed decision-making. The report goes beyond simple market sizing to offer a nuanced understanding of the forces shaping this vital sector.

Detailed Market Overview: A meticulous examination of historical market performance and robust forecasts, encompassing market size, value, volume, share, and growth trends segmented by key parameters. We utilize advanced analytical techniques to provide highly accurate projections.
Competitive Landscape: In-depth profiles of leading players, meticulously analyzing their market share, product portfolios (including innovative formulations and delivery systems), competitive strategies, R&D pipelines, and mergers & acquisitions activity. We identify key competitive advantages and potential threats.
Product Segmentation: Granular market analysis of various contraceptive drug types, including oral contraceptives (combined and progestin-only), injectables (e.g., Depo-Provera), implants (e.g., Nexplanon), emergency contraceptives (e.g., Plan B), intrauterine devices (IUDs), patches, and rings. Growth projections are provided for each segment, considering evolving consumer preferences and technological advancements.
Distribution Channels: A detailed analysis of the distribution landscape, encompassing pharmacies (retail and mail-order), hospitals, clinics (including family planning clinics), online retailers, and wholesalers. We assess the efficiency and reach of each channel, identifying emerging trends and opportunities.
Regulatory Landscape: A thorough review of the current regulatory environment, including FDA approvals, labeling requirements, reimbursement policies, and potential legislative changes impacting the market. We analyze the implications of these regulations on market access and innovation.
Dynamic Market Forces (DROC & Beyond): An in-depth analysis extending beyond just DROC (Drug Resistance, Over-the-Counter switch, and Competitive dynamics) to encompass emerging trends such as telehealth adoption, patient preferences, and the impact of public health initiatives. This section provides a forward-looking perspective on market evolution.
Pricing and Reimbursement Analysis: A comprehensive analysis of pricing strategies, discounts, rebates, and reimbursement rates across different channels and payer types. We identify factors influencing pricing dynamics and their impact on market access and profitability.
Import/Export and Supply Chain Analysis: A detailed examination of the import and export of contraceptive drugs, including key trading partners, supply chain dynamics, and potential disruptions. This assessment considers global sourcing strategies and their implications for market stability.
Intellectual Property Landscape: A review of patents and trademarks held by key players, assessing their impact on market competition and future innovation. This analysis identifies potential opportunities and challenges related to intellectual property rights.

Our report is an indispensable resource for manufacturers, distributors, healthcare providers, investors, and policymakers seeking a comprehensive and actionable understanding of the U.S. Contraceptive Drugs Market. It provides valuable insights to navigate the complexities of this evolving landscape and make strategic decisions to achieve sustainable growth and market leadership.

Enhanced Content:

U.S. Contraceptive Drugs Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 6.8% from 2020-2034
Segmentation	By Distribution Channel Hospital Pharmacy Retail Pharmacy Clinics Online Channels Public Channels & NGOs Others By Geography

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Introduction of Cost-effective Manufacturing Processes to Drive Market Growth
- - 3.3. Market Restrains
  - - 3.3.1. Side Effects Associated with Usage of Contraceptive Drugs to Impede Market Growth
- - 3.4. Market Trends
  - - 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. U.S. Contraceptive Drugs Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Distribution Channel
  - 5.1.1. Hospital Pharmacy
  - 5.1.2. Retail Pharmacy
  - 5.1.3. Clinics
  - 5.1.4. Online Channels
  - 5.1.5. Public Channels & NGOs
  - 5.1.6. Others
- 5.2. Market Analysis, Insights and Forecast - by Region
  - 5.2.1.
6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 Agile Therapeutics (U.S.)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 Johnson & Johnson Services Inc. (U.S.)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 AbbVie Inc. (U.S.)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Pfizer Inc. (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 Teva Pharmaceutical Industries Ltd. (Israel)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Viatris Inc. (U.S.)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 Amneal Pharmaceuticals Inc. (U.S.)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 Bayer AG (Germany)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)

List of Figures

Figure 1: U.S. Contraceptive Drugs Market Revenue Breakdown (USD Billion, %) by Product 2025 & 2033
Figure 2: U.S. Contraceptive Drugs Market Share (%) by Company 2025

List of Tables

Table 1: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 2: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Distribution Channel 2020 & 2033
Table 3: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Region 2020 & 2033
Table 4: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Region 2020 & 2033
Table 5: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 6: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Distribution Channel 2020 & 2033
Table 7: U.S. Contraceptive Drugs Market Revenue USD Billion Forecast, by Country 2020 & 2033
Table 8: U.S. Contraceptive Drugs Market Volume K Units Forecast, by Country 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Contraceptive Drugs Market?

The projected CAGR is approximately 6.8%.

2. Which companies are prominent players in the U.S. Contraceptive Drugs Market?

Key companies in the market include Agile Therapeutics (U.S.), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (U.S.), Amneal Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany).

3. What are the main segments of the U.S. Contraceptive Drugs Market?

The market segments include Distribution Channel.

4. Can you provide details about the market size?

The market size is estimated to be USD 6.25 USD Billion as of 2022.

5. What are some drivers contributing to market growth?

Introduction of Cost-effective Manufacturing Processes to Drive Market Growth.

6. What are the notable trends driving market growth?

Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

7. Are there any restraints impacting market growth?

Side Effects Associated with Usage of Contraceptive Drugs to Impede Market Growth.

8. Can you provide examples of recent developments in the market?

August 2023 – Lupin received U.S. FDA approval for a generic equivalent of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets, known as Turqoz.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Billion and volume, measured in K Units.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "U.S. Contraceptive Drugs Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the U.S. Contraceptive Drugs Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the U.S. Contraceptive Drugs Market?

To stay informed about further developments, trends, and reports in the U.S. Contraceptive Drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Related Reports

Contraceptive Drugs Market 2025 Trends and Forecasts 2033: Analyzing Growth Opportunities

Hormonal Contraceptives Market Strategic Roadmap: Analysis and Forecasts 2025-2033

Contraceptives Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities

Contraceptive Pills Market Insightful Analysis: Trends, Competitor Dynamics, and Opportunities 2025-2033

Contraceptive Devices Market Is Set To Reach 7,013.8 Million By 2033, Growing At A CAGR Of XXX

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report